Navigation Links
Pioneering Medical Technology Company, Optivus Proton Therapy, Inc., Celebrates 20th Anniversary

SAN BERNARDINO, Calif., May 31, 2013 /PRNewswire/ -- No other medical technology company can make the claim they've been solely focused on "Saving Lives with Proton Therapy," for more than 20 years. However, San Bernardino-based Optivus Proton Therapy, Inc. (Optivus) (, a medical device engineering company, is celebrating its 20th Anniversary as pioneers in this high-tech medical technology field, having first launched in 1993.

The 20th Anniversary festivities for Optivus employees and their families will take place on the actual anniversary date of June 1.

"When we started more than 20 years ago, there was an overtone of pessimism in the radiation oncology field about proton beam therapy for the treatment of cancer and other diseases – institutions and radiation oncologists just weren't sure it would ever be profitable or practical," Jon W. Slater , Founder and CEO says. "But proton therapy stood the 'test of time,' and Optivus has come out as a leader within our industry. Our engineering team built the first hospital-based proton treatment center in the world at the Loma Linda University Medical Center in Loma Linda, C.A. (LLUMC)."

"The advances Optivus has made working with the physicians, physicists and scientists at LLUMC and other institutions over the last 20 years have resulted in a highly advanced, efficient and safe medical device," said David Lesyna , Vice President of Engineering.

Optivus President David Stokes remarked, "The key to our longevity is in our commitment to providing safe and efficient technology to benefit cancer patients and their families. Our technology at LLUMC has been used to treat more patients for more disease types than any other center of its kind – more than 17,000 patients by early 2013.  That's nearly a quarter of all patients treated with protons worldwide. You won't find that with any other proton therapy technology provider."

About Proton Radiation Therapy

Proton radiation therapy is the most accurate form of radiation treatment available today. It is ideal for treating cancers of the prostate, brain, lung, and tumors in children as well as many other conditions. The precision of the proton radiation beam allows few to no side effects as healthy tissue surrounding the disease is spared. Ultimately, this results in a better quality of life for the patient both during and after treatment.

About Optivus Proton Therapy, Inc.

In 1988 Loma Linda University Medical Center in Southern California undertook the challenge of building the world's first hospital-based Proton Beam Cancer Treatment Center under the planned Children's Hospital Wing. The facility would consist of three gantry rooms and two fixed-beam rooms.

In October of 1990, the first treatment room was fully operational and shortly thereafter, the original engineering team, led by Jon W. Slater , was entrusted with the technical enhancement and maintenance of the entire treatment center.

To meet future demands for this life-saving technology, within commercial markets, the engineering team transformed into a commercial business entity in 1993. The company was founded on principals of continuous excellence in design and development of this disease treatment technology.

Optivus' product, the Conforma 3000®, is FDA cleared and in its 7th design generation. It is a synchrotron accelerator based system that is modular and scalable to ensure upgrades and enhancements can be achieved without interrupting patient treatment. With over $150M in upgrades since 1990, (after the first patient was treated on the system,) the Optivus system at LLUMC has remained a leader in cutting edge technology.

Lisa Pizzi
Optivus Proton Therapy, Inc.

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Optivus Proton Therapy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jeffrey Epstein, New York Philanthropist, Funds Pioneering Cancer Metastasis Research at Mount Sinai
2. Fifteen Pioneering Inventors Nominated for European Inventor Award
3. Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market
4. Society of Interventional Radiology: Pioneering specialty reaches out
5. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
6. Pioneering the Lap Band to Sleeve Gastrectomy Conversion
7. Somnetics Pioneering CPAP Device Receives the 2012 North American Frost & Sullivan Award for Product Differentiation Excellence
8. Cantel Medical Corp. To Hold Conference Call To Discuss Results for Its Third Quarter Ended April 30, 2013
9. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
10. CCS Medical Announces Enhanced Product Formulary
11. ViewRays Chief Medical Officer Honored by American Society for Radiation Oncology (ASTRO)
Post Your Comments:
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... 24, 2015 --> ... MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects there. ,  ,Our 199-page report ... lucrative areas in the industry and the future market ...
(Date:11/24/2015)... Inc., an industry leader in LCD screen protection and glare-elimination technology, is providing a vital solution ... patient monitoring or electronic documentation system. Photo - ... ... ... A study in 2013 by the National Institutes of ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... ... 24, 2015 , ... Aided by seed funding from the Ron Foley Foundation, ... yield insights into how to detect and treat pancreatic cancer (PC). , WCHN ... non-coding RNA molecules (ncRNA), genetic material that is present in the blood of patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Innovative Blending, a household invention that revolutionizes the vending ... Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):